
vTv Therapeutics (VTVT) Stock Forecast & Price Target
vTv Therapeutics (VTVT) Analyst Ratings
Bulls say
vTv Therapeutics is a biotech company with a promising lead candidate, cadisegliatin, which has received Breakthrough Therapy Designation and is currently in Phase 3 trials for the treatment of Type 1 Diabetes. The drug has shown potential in reducing hypoglycemia and A1C levels, and has a safe dosage of 800mg. The company has a strong financial outlook and is led by a CEO with experience in the pharmaceutical and medical device industry. However, they face risks related to intellectual property, competition, and financing.
Bears say
vTv Therapeutics is a late-stage biopharmaceutical company with a focus on developing treatments for diabetes and other chronic diseases. However, the negative outlook is primarily driven by a lack of confidence in the company's main drug candidate, cadisegliatin, and its ability to receive FDA approval. While management remains optimistic and has made strategic partnerships, the company's financials and lack of pipeline diversity may limit its potential for success.
This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
vTv Therapeutics (VTVT) Analyst Forecast & Price Prediction
Start investing in vTv Therapeutics (VTVT)
Order type
Buy in
Order amount
Est. shares
0 shares